Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists

Journal of Human Hypertension

Volumn 13, Issue , 1999, Pages S3-S10

  Sever, P S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiotensin II AT1 receptor antagonist; Candesartan cilexetil; Organ protection; Review

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; VALSARTAN;

BLOOD PRESSURE REGULATION; BLOOD VESSEL; BRAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART; HUMAN; KIDNEY; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0032905903     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000756     Document Type: Article

References (31)

1. Goodfriend MD, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
2. Johnston CI, Risvanus J. Preclinical pharmacology of angiotensin II receptor antagonists. Am J Hypertens1997; 10: 306S-310S.
3. Burnier M, Waeber B, Brunner HR. The advantages of angiotensin II antagonism. J Hypertens 1994; 12 (Suppl 2): S7-S15.
4. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
5. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-587.
6. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.JHum Hypertens 1997; 11 (Suppl 2): S19-S25.
7. van Lier JJ, van Heiningen PNM, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S27-S28.
8. Riddell JG. A study of the food interaction potential of candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S29-S30.
9. Jonkman JJ Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens1997; 11 (Suppl 2): S31-S35.
10. Lacourcière Y, Lefebvre J. Modulation of the renin- angiotensin-aldosterone system and cough. Can J Cadiol 1995; 11 (Suppl F): 33F-39F.
11. Vleeming W ACE inhibitor-induced angioedema. Incidence, prevention and management. Dnig Safety1998; 18: 171-188.
12. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11 (Suppl 2): S9-S17.
13. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59.
14. Beiz GG Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997; 11 (Suppl 2); S45-S47.
15. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2); S69-S73.
16. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
17. Gradman AH A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension1995; 25: 1345-1350.
18. Oparil S The efficacy and safety of valsarían compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
19. Guthrie R for the Multicenter Investigators. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension. A dou- ble-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998; 15: 217-227.
20. Franke H. Antihypertensive effects of candesartan, enalapril and placebo. J Hum Hypertens 1997; 11 (Suppl 2); S61-S62.
21. Zanchetti A, Omboni S, Di Biago C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens1997; 11 (Suppl 2): S57-S59.
22. Farsang C Antihypertensive effects and toler-ability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10 (4 pt 2): 80A.
23. Philipp T, Letzel H. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens1997; 11 (Suppl 2): S67-S68.
24. Plouin P-F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997; 11 (Suppl 2): S65-S66.
25. MacGregor GA, Antonios TF, He FJ. The efficacy of candesartan, an angiotensin II type 1 receptor antagonist, alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in patients with moderate-to-severe essential hypertension. Am J Hypertens 1997; 10 (4 Pt 2): 112A.
26. Stearns RA, Chakravarty PK, Chen R et al. Biotransformation of losarían to its active carboxylic acid metabolite in human liver microsomes. Drug Metab Dispos 1995; 23; 207-215.
27. Belcher G Candesartan cilexetil: safety and toler- ability in healthy volunteers and patients with hyper-tension. J Hum Hypertens 1997; 11 (Suppl 2): S85- S89.
28. Mclnnes GT The efficacy and tolerability of can- desartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-S80.
29. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (Suppl 2): S81-S83.
30. Inada Y Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19(7); 1079-1099.
31. Azizi M Is the differentiation of AT, receptor antagonists feasible in normotensive volunteers?Hypertens 1997; 15 (Suppl 4): S1-16.